Aptimmune Biologics and Kemin Industries Announce Partnership
This week, Aptimmune Biologics and Kemin Industries officially announced their partnership in the global vaccine industry, according to a news release from the company. On July 31, 2018, Kemin became an equity shareholder in Aptimmune and has exclusive rights to its vaccines and vaccine technologies outside the U.S., the release stated.
As part of the Kemin-Aptimmune partnership, the companies have formed Kemin Biologics, which will manufacture and market Aptimmune’s proprietary Barricade swine vaccine technology and products outside the U.S.
Andy Smythe, Technical Sales and Marketing Director for Aptimmune Biologics, said the relationship with Kemin is an ideal fit for both companies.
“Kemin has a strong global presence and is focused on providing innovative nutritional and health solutions for a changing world,” Smythe said in the release. “We are very excited to combine Aptimmune’s expertise in mucosal vaccine technology with Kemin’s global business vision.”
In the U.S. market, Aptimmune will retain development, sales and marketing responsibilities for its intellectual property and existing vaccine products made with Barricade technology. The Kemin Biologics partnership will be managed by representatives from both companies.
“With this new partnership and the creation of Kemin Biologics, Kemin will work with Aptimmune to achieve synergies and provide worldwide reach to new vaccine technologies developed through this partnership,” said GS Ramesh, Global Group President of Animal Nutrition and Health for Kemin Industries, in the release. “We see great potential in the marketplace for vaccines and are optimistic about this new business venture for Kemin.”
Both parties believe this partnership is ideal, as it brings together Kemin’s long-standing dedication to novel and value-added products in the global marketplace and Aptimmune’s unique and field-tested Barricade swine product portfolio.
The new partnership “will allow the R&D teams to advance new programs in the swine respiratory disease field for swine producers here in the U.S., and Kemin can focus on expanding the platform in key international markets,” said Robert Nordgren, chairman of the board for Aptimmune.
Vetagro Sponsors 2018 Foundation for Food and Agriculture Research Fellow Award
Vetagro announces a landmark sponsorship with the Foundation for Food and Agriculture Research (FFAR) for its Fellow Program, in a recent news release. The FFAR Fellows Program will fund 48 graduate students over three years using an interdisciplinary approach to career readiness. Students will pursue research projects in an area of food or agriculture research related to FFAR’s Challenge Areas and strategic initiatives. In addition to academic advisors, students will be matched with industry mentors who will provide additional career guidance.
“This sponsorship is part of Vetagro’s ongoing commitment to an innovative and science-based R&D - explains Andrea Piva, president of Vetagro. “The FFAR program aims to support the next generation of food and agriculture researchers and we are thrilled to be part of this journey.”
This week, the 17 inaugural recipients of the 2018 FFAR Fellow award were announced and Vetagro is the proud industry sponsor of Ananda Portela Fontoura.
Fontoura is a stipend and professional development FFAR Fellow in the Department of Animal Science at Cornell University’s College of Agriculture and Life Sciences, the release said. Her work involves defining nutritional therapies that can improve the metabolic health and productivity of dairy cows at the onset of lactation and when exposed to heat stress.
“Supporting this research contributes to the evolution of current feeding systems and allows an advancement of animal production,” Piva said the release. “We wish all the best to Fontura!”